122 related articles for article (PubMed ID: 24997182)
1. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study.
Boyer DS; Goldbaum M; Leys AM; Starita C;
Br J Ophthalmol; 2014 Nov; 98(11):1543-6. PubMed ID: 24997182
[TBL] [Abstract][Full Text] [Related]
2. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
3. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.
Frenkel RE; Mani L; Toler AR; Frenkel MP
Am J Ophthalmol; 2007 Jun; 143(6):1034-5. PubMed ID: 17524771
[TBL] [Abstract][Full Text] [Related]
4. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
5. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections.
Lemos V; Cabugueira A; Noronha M; Abegão Pinto L; Reina M; Branco J; Gomes T
Ophthalmologica; 2015; 233(3-4):162-8. PubMed ID: 25791262
[TBL] [Abstract][Full Text] [Related]
6. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.
Hariprasad SM; Shah GK; Blinder KJ
Am J Ophthalmol; 2006 Jan; 141(1):200-1. PubMed ID: 16387003
[TBL] [Abstract][Full Text] [Related]
7. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
[TBL] [Abstract][Full Text] [Related]
8. Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma.
Lanzl IM; Maier M; Feucht N; Lohmann CP; Kotliar KE
Am J Ophthalmol; 2008 Jan; 145(1):185; author reply 186. PubMed ID: 18154762
[No Abstract] [Full Text] [Related]
9. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
[TBL] [Abstract][Full Text] [Related]
10. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
[TBL] [Abstract][Full Text] [Related]
11. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
12. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients.
Murray CD; Wood D; Allgar V; Walters G; Gale RP
Eye (Lond); 2014 Oct; 28(10):1218-22. PubMed ID: 25081290
[TBL] [Abstract][Full Text] [Related]
13. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Kim JE; Mantravadi AV; Hur EY; Covert DJ
Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
[TBL] [Abstract][Full Text] [Related]
14. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
[TBL] [Abstract][Full Text] [Related]
15. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
Kiddee W; Montriwet M
PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema.
Al-Abdullah AA; Nowilaty SR; Asghar N; Al-Kharashi AS; Ghazi NG
Retina; 2015 Mar; 35(3):440-8. PubMed ID: 25285810
[TBL] [Abstract][Full Text] [Related]
17. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
18. SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS: What Is the Evidence?
Dedania VS; Bakri SJ
Retina; 2015 May; 35(5):841-58. PubMed ID: 25905784
[TBL] [Abstract][Full Text] [Related]
19. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study.
Knip MM; Välimäki J
Acta Ophthalmol; 2012 May; 90(3):254-8. PubMed ID: 20456259
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study).
Ishibashi T;
Jpn J Ophthalmol; 2013 Sep; 57(5):417-23. PubMed ID: 23860781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
